Research Developments in Psoriatic Arthritis

Released On
December 31, 2020

Expires On
December 30, 2021

Media Type

Completion Time
45 minutes



Scroll to the Bottom of this Information to Begin this Course

Sponsored by the Annenberg Center for Health Sciences at Eisenhower.

This activity is supported by an independent educational grant from Janssen Biotech, Inc.

Credit Available

  • Physicians — maximum of .75 AMA PRA Category 1 Credit(s)

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This activity was developed for rheumatologists, primary care physicians and other healthcare providers who manage patients with rheumatoid arthritis.

Program Overview

The latest research related to the treatment of patients with psoriatic arthritis is often first made public at the American College of Rheumatology (ACR) annual meeting. In this CME activity, Dr. Roy Fleischmann discusses three posters presented at ACR Convergence 2020. Dr. Fleischmann summarizes the methods and results of each posters and provides his own thoughts as to the importance of the research findings and implications for clinical practice in the treatment of patients with psoriatic arthritis.

Content Areas

  • Guselkumab
  • Upadacitinib
  • Ustekinumab

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Summarize the latest research developments in the treatment of psoriatic arthritis
  • Describe how new data and recommendations can impact clinical practices to improve care
  • Incorporate evidence-based research into clinical practice


Roy M. Fleischmann, MD

Roy M. Fleischmann, MD

Clinical Professor of Medicine
University of Texas Southwestern Medical Center
Medical Director
Metroplex Clinical Research Center
Dallas, Texas

Accreditation Statement

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of .75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures of Conflicts of Interest

Roy M. Fleischmann, MD

  • Consultant: AbbVie, Amgen, Eli Lilly, GSK, Pfizer, UCB
  • Research Support: AbbVie, Amgen, BMS, Eli Lilly, GSK, Pfizer, Sanofi, TEVA, UCB

Additional content planners
The following have no significant relationship to disclose:
Greg Scott, PharmD (Medical writer)
Eugene Cullen, MD (Peer Reviewer)

Annenberg Center for Health Sciences
Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

Instructions for Participation and Credit

This activity is an online enduring material. Successful completion is achieved by reading and/or viewing the materials, reflecting on its implications in your practice, and completing the assessment component.

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:

  1. Read the CME/CE information and faculty disclosures.
  2. Participate in the online activity.
  3. Submit the evaluation form.

Certificates will be emailed to the participant

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Disclosure of Unlabeled Use

The faculty for this activity has disclosed that there will be discussion about the use of products for non-FDA approved indications


The ideas and opinions presented in this educational activity are those of the faculty and do not necessarily reflect the views of the Annenberg Center and/or its agents. As in all educational activities, we encourage practitioners to use their own judgment in treating and addressing the needs of each individual patient, taking into account that patient’s unique clinical situation. The Annenberg Center disclaims all liability and cannot be held responsible for any problems that may arise from participating in this activity or following treatment recommendations presented.

Contact Information

For help or questions about this activity please contact Continuing Education:
Annenberg Center for Health Sciences
39000 Bob Hope Drive
Dinah Shore Building
Rancho Mirage, CA 92270
Phone 760-773-4500
Fax 760-773-4513
8 AM – 5 PM, Pacific Time, Monday – Friday .